ERBB2 and breast cancer: When expressed using percentages of patients, 10.1% of basal, 5.2% of Luminal B, 4.5% of Her2+, 2.5% of Claudin-Low, and none of the Luminal A and Normal-like breast cancers overexpressed Nek2 (Supp.